Mick M. Van Eijs

Utrecht, UT 3584CX, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Clinical and endoscopic features of checkpoint inhibitor-induced colitis and their association with selective immunosuppressive therapy use.

Clinical and endoscopic features of checkpoint inhibitor-induced colitis and their association with selective immunosuppressive therapy use.

Journal: Inflammatory bowel diseases

Published: March 22, 2026

Author Correction: Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events.

Author Correction: Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events.

Journal: Communications medicine

Published: January 23, 2026

Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events.

Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events.

Journal: Communications medicine

Published: March 05, 2025

Gut microbiome and immune checkpoint inhibitor toxicity.

Gut microbiome and immune checkpoint inhibitor toxicity.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 13, 2024

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 14, 2024

In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients.

In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients.

Journal: Cancer immunology, immunotherapy : CII

Published: May 08, 2024

Physical activity and checkpoint inhibition: association with toxicity and survival.

Physical activity and checkpoint inhibition: association with toxicity and survival.

Journal: Journal of the National Cancer Institute

Published: September 20, 2023

Clinical and translational attributes of immune-related adverse events.

Clinical and translational attributes of immune-related adverse events.

Journal: Nature cancer

Published: August 31, 2023

Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor colitis.

Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor colitis.

Journal: iScience

Published: May 05, 2023

Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition.

Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition.

Journal: Cancer immunology, immunotherapy : CII

Published: March 31, 2023

Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies.

Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 12, 2023

Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance.

Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance.

Journal: NPJ precision oncology

Published: December 22, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026